Almac acquires BioClin as analytical services business grows
Headquartered in Craigavon, Northern Ireland, the Almac Group is contract development and manufacturing organization (CDMO) providing a range of services.
BioClin provides analytical services, including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing, and GLP bioanalysis. The company’s 14,000 square foot facility – located in Athlone, Ireland, two hours from Almac’s headquarters in Craigavon – is GLP certified (INAB), cGMP certified (HPRA) and FDA registered.
“Acquiring BioClin was attractive to Almac’s Sciences because of the facilities and skilled staff the business provides in the field of pharmaceutical and biopharmaceutical analysis,” John Robson, vice president quality operations, Almac Sciences, told Outsourcing-Pharma.com.
“Due to increasing global client requirements, analytical services has been a growing area of business for Almac Sciences in the past few years and this acquisition provides an extension of capabilities offered from its HQ site in Northern Ireland and the US,” Robson added.
Following the completed acquisition, BioClin’s employees will join Almac Sciences’ network of almost 600 employees – part of the Almac Group’s nearly 5,000 staff worldwide.
The acquisition follows a successful inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) at the Almac’s new pharmaceutical development and manufacturing facilities at its Charnwood Campus in Loughborough. The site is now able to develop, manufacture, and pack non-potent and potent, solid oral drug products for clinical trials and commercial supply.
Also recently, Almac announced that Arran Chemical Company – which Almac purchased in November 2015 – has completed its first phase of a three-part strategic plan dubbed “Arran Deploys Advanced Production Technologies” or ADAPT. The plan involves a multi-million Euro investment to grow the company’s manufacturing capacity and production technology portfolio.